Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of GEC255, a novel KRASG12C inhibitor, in advanced solid tumors

被引：0
|
作者：
Zhang, Yan
Zhou, Lin
Gong, Youling
Huang, Meijuan
Tang, Min
Liu, Yongmei
Yu, Min
Xiu, Weigang
Liang, Xinjun
Liu, Xinyu
Fu, Xin-Yuan
Lu, You
机构：
[1] Sichuan Univ, Dept Thorac Oncol, Canc Ctr, West China Hosp, Chengdu, Peoples R China
[2] Sichuan Univ, West China Hosp, Canc Ctr, Thorac Oncol Ward, Chengdu, Peoples R China
[3] Sichuan Univ, West China Hosp, State Key Lab Biotherapy, Chengdu, Peoples R China
[4] West China Hosp, Sch Med, Dept Thorac Oncol, Canc Ctr, Chengdu, Peoples R China
[5] Hubei Canc Hosp, Dept Med Oncol, Wuhan, Peoples R China
[6] GenEros Biopharma Ltd, Clin Dev Dept, Hangzhou, Peoples R China
[7] Sichuan Univ, Inst Human Dis & Immunotherapy, West China Hosp, Chengdu, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
9112
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Phase 1 study evaluating the safety, tolerability, pharmacokinetics (PK), and efficacy of AMG 510, a novel small molecule KRASG12c inhibitor, in advanced solid tumors.
    Fakih, Marwan
    O'Neil, Bert
    Price, Timothy Jay
    Falchook, Gerald Steven
    Desai, Jayesh
    Kuo, James
    Govindan, Ramaswamy
    Rasmussen, Erik
    Morrow, Phuong Khanh H.
    Ngang, Jude
    Henary, Haby A.
    Hong, David S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [2] Phase 1 Study of Safety, Tolerability, PK and Efficacy of AMG 510, a Novel KRASG12C Inhibitor, Evaluated in NSCLC
    Govindan, R.
    Fakih, M.
    Price, T.
    Falchook, G.
    Desai, J.
    Kuo, J.
    Strickler, J.
    Krauss, J.
    Li, B.
    Denlinger, C.
    Durm, G.
    Ngang, J.
    Henary, H.
    Ngarmchamnanrith, G.
    Rasmussen, E.
    Morrow, P.
    Hong, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S208 - S208
  • [3] A phase 1 clinical trial to evaluate safety, tolerability, pharmacokinetics (PK) and efficacy of D-1553, a novel KRASG12C inhibitor, in patients with advanced or metastatic solid tumor harboring KRASG12C mutation.
    Price, Timothy
    Grewal, Jaspreet
    Abed, Afaf
    Moore, Melissa
    Yeh, Yu-Min
    Gadgeel, Shirish
    Richardson, Gary
    Underhill, Craig
    Ganju, Vinod
    Lee, Keun-Wook
    Huh, Seok Jae
    Kim, Sang-We
    Yang, Chih-Hsin
    Chen, Yuh-Min
    Xiang, Ziyong
    Shi, Zhe
    Wang, Yaolin
    Zhang, Ling
    Millward, Michael
    CANCER RESEARCH, 2022, 82 (12)
  • [4] Phase 1 Trial Evaluating Safety, Efficacy, and PK of AMG 510, a Novel KRASG12C Inhibitor, in Non-Small Cell Lung Cancer
    Govindan, R.
    Fakih, M. G.
    Price, T. J.
    Falchook, G. S.
    Desai, J.
    Kuo, J. C.
    Strickler, J. H.
    Krauss, J. C.
    Li, B. T.
    Denlinger, C. S.
    Durm, G.
    Ngang, J.
    Henary, H.
    Ngarmchamnanrith, G.
    Rasmussen, E.
    Morrow, P. K.
    Hong, D. S.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1191 - S1192
  • [5] A phase 1b study evaluating the safety and efficacy of sotorasib, a KRASG12C inhibitor, in combination with trametinib, a MEK inhibitor, in KRAS p.G12C-Mutated Solid Tumors
    Ramalingam, Suresh
    Fakih, Marwan
    Strickler, John
    Govindan, Ramaswamy
    Li, Bob T.
    Goldberg, Sarah
    Gandara, David
    Burns, Timothy
    Barve, Minal
    Shu, Catherine
    Frank, Richard
    Sohal, Davendra
    Jafarinasabian, Pegah
    Dai, Tian
    Mather, Omar
    Hong, David
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (12)
  • [6] A phase 1 study evaluating the pharmacokinetics (PK), safety, and efficacy of regorafenib (REG) in Chinese patients with advanced, refractory solid tumors
    Cao, J.
    Ji, D.
    Shen, W.
    Wang, Q.
    Liu, Y.
    Lu, D.
    Sturm, I.
    Huang, F.
    Cleton, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [7] Efficacy and toxicity of KRASG12C inhibitors in advanced solid tumors: a meta-analysis
    Dang, Shoutao
    Zhang, Shuyang
    Zhao, Jingyang
    Li, Wei
    WORLD JOURNAL OF SURGICAL ONCOLOGY, 2024, 22 (01)
  • [8] Safety, Efficacy, and Pharmacokinetics of AMG 510, a Novel KRASG12C Inhibitor, in Patients with Non-Small Cell Lung Cancer
    Govindan, R.
    Fakih, M.
    Price, T.
    Falchook, G.
    Desai, J.
    Kuo, J.
    Strickler, J.
    Krauss, J.
    Li, B.
    Denlinger, C.
    Durm, G.
    Ngang, J.
    Henary, H.
    Ngarmchamnanrith, G.
    Rasmussen, E.
    Morrow, P. K.
    Hong, D.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (11) : S1125 - S1126
  • [9] Phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
    Soria, J. -C.
    DeBraud, F.
    Bahleda, R.
    Adamo, B.
    Andre, F.
    Dientsmann, R.
    Delmonte, A.
    Cereda, R.
    Isaacson, J.
    Litten, J.
    Allen, A.
    Dubois, F.
    Saba, C.
    Robert, R.
    D'Incalci, M.
    Zucchetti, M.
    Camboni, M. G.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2014, 25 (11) : 2244 - 2251
  • [10] A phase I/IIa study evaluating the safety, efficacy, pharmacokinetics, and pharmacodynamics of lucitanib in advanced solid tumors
    Soria, Jean-Charles
    De Braud, Filippo G.
    Bahleda, Ratislav
    Adamo, Barbara
    Cereda, Roberta
    Camboni, Maria Gabriella
    Robert, Renate
    Isaacson, Jeffrey D.
    Litten, Jason B.
    Allen, Andrew R.
    Rolfe, Lindsey
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
12345